{"organizations": [], "uuid": "019f3c12fbd6850a0c378e4846bee5a94b2a3487", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-celgene-to-acquire-remaining-share/brief-celgene-to-acquire-remaining-shares-of-juno-therapeutics-for-87-per-share-idUSASB0C1NE", "country": "US", "domain_rank": 408, "title": "BRIEF-Celgene To Acquire Remaining Shares Of Juno Therapeutics For $87 Per Share", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-22T13:36:00.000+02:00", "replies_count": 0, "uuid": "019f3c12fbd6850a0c378e4846bee5a94b2a3487"}, "author": "", "url": "https://www.reuters.com/article/brief-celgene-to-acquire-remaining-share/brief-celgene-to-acquire-remaining-shares-of-juno-therapeutics-for-87-per-share-idUSASB0C1NE", "ord_in_thread": 0, "title": "BRIEF-Celgene To Acquire Remaining Shares Of Juno Therapeutics For $87 Per Share", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "celgene corp", "sentiment": "none"}, {"name": "celgene corp", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "celgene", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 36 AM / in 13 minutes BRIEF-Celgene To Acquire Remaining Shares Of Juno Therapeutics For $87 Per Share Reuters Staff \nJan 22  : \n* CELGENE CORPORATION TO ACQUIRE JUNO THERAPEUTICS, INC., ADVANCING GLOBAL LEADERSHIP IN CELLULAR IMMUNOTHERAPY \n* CELGENE CORPORATION TO ACQUIRE JUNO THERAPEUTICS, INC., ADVANCING GLOBAL LEADERSHIP IN CELLULAR IMMUNOTHERAPY * CELGENE CORP - DEAL FOR $87 PER SHARE \n* CELGENE CORP - REAFFIRMING 2020 FINANCIAL TARGETS OF $19B-$20B IN TOTAL NET PRODUCT SALES AND ADJUSTED EPS GREATER THAN $12.50 \n* CELGENE CORP - ‍TRANSACTION WAS APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES​ \n* CELGENE CORP - JCAR017 IS EXPECTED TO BE SIGNIFICANT GROWTH DRIVER BEYOND 2020 WITH POTENTIAL GLOBAL PEAK SALES OF APPROXIMATELY $3 BILLION \n* CELGENE CORP - CELGENE WILL PAY APPROXIMATELY $9 BILLION, NET OF CASH AND MARKETABLE SECURITIES ACQUIRED AND JUNO SHARES ALREADY OWNED BY CELGENE \n* CELGENE CORP - ‍ACQUISITION IS EXPECTED TO BE DILUTIVE TO ADJUSTED EPS IN 2018 BY APPROXIMATELY $0.50​ \n* CELGENE CORP - ‍REGULATORY APPROVAL FOR JCAR017 IN U.S. IS EXPECTED IN 2019 WITH POTENTIAL GLOBAL PEAK SALES OF APPROXIMATELY $3 BILLION​ \n* CELGENE CORP - DEAL ‍IS EXPECTED TO BE INCREMENTALLY ADDITIVE TO NET PRODUCT SALES IN 2020​ \n* CELGENE CORP - CELGENE EXPECTS TO FUND TRANSACTION THROUGH A COMBINATION OF EXISTING CASH AND NEW DEBT \n* CELGENE CORP - REGULATORY APPROVAL FOR JCAR017 IN U.S. IS EXPECTED IN 2019 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-22T13:36:00.000+02:00", "crawled": "2018-01-22T13:56:29.018+02:00", "highlightTitle": ""}